{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:21:32Z","timestamp":1790310092792,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81500522"],"award-info":[{"award-number":["81500522"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013365","name":"Sichuan University West China Hospital","doi-asserted-by":"publisher","award":["ZYGD23001"],"award-info":[{"award-number":["ZYGD23001"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.euo.2025.09.015","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:08:29Z","timestamp":1760659709000},"page":"1607-1616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Endoscopic Thulium Laser Ablation with Disitamab Vedotin and Immunotherapy in High-risk Upper Tract Urothelial Carcinoma: A Prospective Pilot Study of a Novel Kidney-sparing Strategy"],"prefix":"10.1016","volume":"8","author":[{"given":"Jianjun","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyang","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banghua","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengni","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4002-5467","authenticated-orcid":false,"given":"Yige","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.09.015_b0005","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","article-title":"European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2023 update","volume":"84","author":"Roupr\u00eat","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.09.015_b0010","doi-asserted-by":"crossref","first-page":"8201","DOI":"10.1007\/s00432-023-04771-6","article-title":"Trends in the incidence of urothelial carcinoma in Taiwan after the ban on aristolochic acid-containing Chinese herbal preparations, 2001\u20132018: a national population-based cohort study","volume":"149","author":"Liao","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.euo.2025.09.015_b0015","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.juro.2016.11.094","article-title":"A multi-institutional comparison of clinicopathological characteristics and oncologic outcomes of upper tract urothelial carcinoma in China and the United States","volume":"197","author":"Singla","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.09.015_b0020","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.euf.2018.03.003","article-title":"The impact of preoperative severe renal insufficiency on poor postsurgical oncological prognosis in patients with urothelial carcinoma","volume":"5","author":"Momota","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.09.015_b0025","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/bju.16569","article-title":"The impact of post-nephroureterectomy surgically induced chronic kidney disease on survival outcomes","volume":"135","author":"Puri","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.09.015_b0030","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.3390\/jcm12154907","article-title":"Endoscopic conservative treatment of upper urinary tract urothelial carcinoma with a thulium laser: a systematic review","volume":"12","author":"Candela","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.euo.2025.09.015_b0035","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s00345-024-05032-y","article-title":"Endoscopic intervention versus radical nephroureterectomy for the management of localized upper urinary tract urothelial carcinoma: a systematic review and meta-analysis of comparative studies","volume":"42","author":"Giulioni","year":"2024","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2025.09.015_b0040","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.euf.2022.11.016","article-title":"Oncologic and safety outcomes for endoscopic surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: an updated systematic review and meta-analysis","volume":"9","author":"Kawada","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.09.015_b0045","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2025.09.015_b0050","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.09.015_b0055","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.annonc.2024.12.002","article-title":"Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib\/II dose-escalation and dose-expansion study","volume":"36","author":"Zhou","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.09.015_b0060","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1464-410X.2012.11649.x","article-title":"Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy","volume":"112","author":"Xylinas","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.09.015_b0065","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1089\/end.2010.0276","article-title":"Third prize: the role of endoscopic nephron-sparing surgery in the management of upper tract urothelial carcinoma","volume":"25","author":"Raymundo","year":"2011","journal-title":"J Endourol"},{"key":"10.1016\/j.euo.2025.09.015_b0070","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nrurol.2015.24","article-title":"Risk-adapted strategy for the kidney-sparing management of upper tract tumours","volume":"12","author":"Seisen","year":"2015","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2025.09.015_b0075","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.euo.2023.11.017","article-title":"Longer is better for endoscopic follow-up of upper tract urothelial carcinoma after ureteroscopic treatment: an evaluation spanning 10 years of data","volume":"7","author":"Figaroa","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.09.015_b0080","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00345-016-1871-x","article-title":"HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC)","volume":"35","author":"Soria","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2025.09.015_b0085","article-title":"Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients","volume":"15","author":"Zhu","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.euo.2025.09.015_b0090","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1016\/j.asjsur.2024.04.161","article-title":"Discordance of HER2 expression in primary and recurrent\/metastatic urothelial carcinoma in the upper tract","volume":"47","author":"Ye","year":"2024","journal-title":"Asian J Surg"},{"key":"10.1016\/j.euo.2025.09.015_b0095","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nm.4239","article-title":"Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer","volume":"23","author":"Carter","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2025.09.015_b0100","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrm2216","article-title":"Pathways of clathrin-independent endocytosis","volume":"8","author":"Mayor","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.euo.2025.09.015_b0105","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.4161\/cbt.7.10.6585","article-title":"A combination of trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells","volume":"7","author":"Raja","year":"2008","journal-title":"Cancer Biol Ther"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125002500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125002500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T08:40:21Z","timestamp":1778143221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125002500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2588931125002500"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.09.015","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endoscopic Thulium Laser Ablation with Disitamab Vedotin and Immunotherapy in High-risk Upper Tract Urothelial Carcinoma: A Prospective Pilot Study of a Novel Kidney-sparing Strategy","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}